Publications by authors named "A Giaquinto"
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.
View Article and Find Full Text PDFChanges in Breast Cancer Screening Prevalence in the United States during the COVID-19 Pandemic, 2018 to 2022.
Cancer Epidemiol Biomarkers Prev
January 2025
Article Synopsis
- - Annual mammography screening in the U.S. declined for the first time since 2018, with up-to-date screening dropping from 78.7% in 2018 to 76.6% in 2022, indicating 747,791 fewer women met the screening recommendations.
- - Although there was a slight increase in past-year breast cancer screening (from 57.9% to 59.6% between 2020 and 2022), significant disparities were noted, particularly among American Indian/Alaska Native women and those with lower educational levels.
- - The study highlights the ongoing impact of the COVID-19 pandemic on women's health screenings and calls for further research to understand how these trends affect breast cancer diagnosis
This is the American Cancer Society's biennial update of statistics on breast cancer among women based on high-quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Breast cancer incidence continued an upward trend, rising by 1% annually during 2012-2021, largely confined to localized-stage and hormone receptor-positive disease. A steeper increase in women younger than 50 years (1.
View Article and Find Full Text PDFSkeletal anomalies represent a characteristic feature of type 1 Gaucher disease (GD1). Here we evaluated the impact of an integrated therapy comprising enzyme-replacement therapy (ERT), cholecalciferol, and a normocalcemic-normocaloric-hyposodic diet (bone diet) on bone health in GD1 patients. We also performed a systematic review to compare our results with available data.
View Article and Find Full Text PDFArticle Synopsis
- * The incidence of ER-positive breast cancer increased steadily until 2019 but saw a significant drop of 10.2% in 2020; meanwhile, ER-negative cancer rates decreased annually from 2004 to 2012 but also dropped by 6% from 2019 to 2020.
- * Overall trends indicated that while young women and certain ethnic groups experienced rising rates of ER-positive cancer until 2019, ER-negative rates have stabilized, signaling a shift in previous expectations for breast cancer incidence